1. HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.
- Author
-
Lanca AM, Collares JK, Ferreira JL, Lima DM, Brigido LF, Rodrigues R, and Fonseca BA
- Subjects
- Adult, Alkynes, Benzoxazines therapeutic use, CD4 Lymphocyte Count, Cohort Studies, Cyclopropanes, Double-Blind Method, Female, HIV Infections immunology, HIV Infections virology, HIV-1 drug effects, Humans, Lopinavir therapeutic use, Male, Prospective Studies, Treatment Outcome, Viral Load, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, HIV Infections drug therapy, HIV-1 physiology, Viral Tropism drug effects
- Abstract
While human immunodeficiency virus (HIV)-1 chemokine co-receptors 5 tropism and the GWGR motif in the envelope third variable region (V3 loop) have been associated with a slower disease progression, their influence on antiretroviral response remains unclear. The impact of baseline V3 characteristics on treatment response was evaluated in a randomised, double blind, prospective cohort study with patients initiating highly active antiretroviral therapy with lopinavir or efavirenz plus azithothymidine/3TC (1:1) over 48 weeks. Similar virological and immunological responses were observed for both treatment regimens. The 43 individuals had a mean baseline CD4 T cell count of 119 cells/mm(3) [standard deviation (SD) = 99] and a mean viral load of 5.09 log(10) copies/mL (SD = 0.49). The GWGR motif was not associated with a CD4 T cell response, but predicted R5 tropism by the geno2pheno([clinical20%]) algorithm correlated with higher CD4 T cell levels at all monitoring points (p < 0.05). Moreover, higher false-positive rates (FPR) values from this analysis revealed a strong correlation with CD4 T cell recovery (p < 0.0001). Transmitted drug resistance mutations, documented in 3/41 (7.3%) cases, were unrelated to the assigned antiretroviral regimen and had no impact on patient outcomes. In conclusion, naÏve HIV-1 R5 infected patients exhibited higher CD4 T cell counts at baseline; this difference was sustained throughout therapy. The geno2pheno([clinical]) option FPR positively correlated with CD4 T cell gain and may be useful in predicting CD4 T cell recovery.
- Published
- 2012
- Full Text
- View/download PDF